Literature DB >> 11393706

Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.

M C Rouan1, F Marfil, P Mangoni, R Séchaud, H Humbert, G Maurer.   

Abstract

ICL670 is a representative of a new class of orally active tridentate selective iron chelators. Two molecules of ICL670 are required to form a complete hexacoordinate chelate Fe-[ICL670]2 with one ferric iron. A simple and rapid HPLC-UV method for the separate determination of ICL670 and Fe-[ICL670]2 in the plasma of iron-overloaded patients is described. Plasma samples were prepared as rapidly as possible, the tubes being kept at 4 degrees C. Plasma proteins were precipitated with methanol. The supernatant was diluted with water and placed on the refrigerated sample rack of an autosampler before injection. The chromatographic separations were achieved on an Alltima C18 column using 0.05 M Na2HPO4 and 0.01 M tetrabutylammonium hydrogen sulfate-acetonitrile-methanol (41:9:50, v/v/v) as mobile phase. The analytes were detected at 295 nm. Calibration and quality control samples were prepared in normal human plasma. The mean accuracy (n=6) over the entire investigated concentration range 0.25-20 microg/ml ranged from 91 to 109% with a coefficient of variation (C.V.) from 4 to 8% for ICL670, and from 95 to 105% with a C.V. from 2 to 20% for the iron complex. The dissociation of the complex during analysis was shown to be marginal. The iron removal from plasma of iron-overloaded patients by free ICL670 during analysis was low. The in vitro iron transfer from the iron pools of iron-overloaded plasma onto ICL670 was shown to be a slow process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393706     DOI: 10.1016/s0378-4347(01)00079-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  8 in total

1.  Diagnosis of Systemic Diseases Using Infrared Spectroscopy: Detection of Iron Overload in Plasma-Preliminary Study.

Authors:  Leonardo Barbosa Leal; Marcelo Saito Nogueira; Jandinay Gonzaga Alexandre Mageski; Thiago Pereira Martini; Valério Garrone Barauna; Leonardo Dos Santos; Luis Felipe das Chagas E Silva de Carvalho
Journal:  Biol Trace Elem Res       Date:  2021-01-07       Impact factor: 3.738

2.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

3.  Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

Authors:  G Lescoat; K Chantrel-Groussard; N Pasdeloup; H Nick; P Brissot; F Gaboriau
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

4.  Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

Authors:  Deborah Chirnomas; Amber Lynn Smith; Jennifer Braunstein; Yaron Finkelstein; Luis Pereira; Anke K Bergmann; Frederick D Grant; Carole Paley; Michael Shannon; Ellis J Neufeld
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

5.  What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.

Authors:  Carmen Fucile; Francesca Mattioli; Valeria Marini; Massimo Gregori; Aurelio Sonzogni; Antonietta Martelli; Natalia Maximova
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423

Review 6.  Clinical pharmacology of deferasirox.

Authors:  Chiaki Tanaka
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 5.577

7.  Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment.

Authors:  Natalia Maximova; Massimo Gregori; Roberto Simeone; Aurelio Sonzogni; Giulia Boz; Carmen Fucile; Valeria Marini; Antonietta Martelli; Francesca Mattioli
Journal:  Oncotarget       Date:  2017-06-28

8.  Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma.

Authors:  Hung-Ju Lin; Chun-Chi Wang; Hwang-Shang Kou; Cheng-Wei Cheng; Shou-Mei Wu
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.